Literature DB >> 2087297

Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings.

C L Shields1, J A Shields, U Karlsson, H Menduke, L W Brady.   

Abstract

A review of 1019 patients with posterior uveal melanomas, who were treated with episcleral plaque radiotherapy between April 1976 and December 1987, showed that 59 (6%) of these patients have thus far required enucleation of the affected eye. The most common clinical reasons for enucleation were tumor regrowth (51%) and neovascular glaucoma (31%). These irradiated melanomas were of mixed cell type in 40 cases (68%), spindle in 10 cases (17%), totally necrotic in 7 cases (12%), and epithelioid in 2 cases (3%). Some degree of tumor necrosis was seen in all cases. Overall, the median number of mitoses per 40 high-power fields in these irradiated tumors was 0. Most (64%) of the tumors had no identifiable mitosis in 40 high-power fields. A three-way simultaneous comparison of the following groups was made: irradiated eyes enucleated for tumor regrowth, irradiated eyes enucleated for neovascular glaucoma, and a matched group of nonirradiated posterior uveal melanomas. This comparison showed that the largest tumor dimension was significantly greater in the irradiated eyes enucleated for tumor regrowth than in the other two groups. Mitotic activity was significantly higher in the irradiated tumor regrowth and nonirradiated groups than in the irradiated neovascular group. There was no significant difference among the three groups in an analysis of height. The results suggested that mitotic activity may exist after plaque radiotherapy, especially when there is clinical evidence of tumor regrowth.

Entities:  

Mesh:

Year:  1990        PMID: 2087297     DOI: 10.1016/s0161-6420(90)32363-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

Review 1.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

2.  Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.

Authors:  J Pe'er; F H Stefani; S Seregard; T Kivela; P Lommatzsch; J U Prause; B Sobottka; B Damato; I Chowers
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

3.  Imaging the microcirculation of untreated and treated human choroidal melanomas.

Authors:  A J Mueller; D U Bartsch; U Schaller; W R Freeman; A Kampik
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

4.  Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma.

Authors:  E Messmer; N Bornfeld; M Foerster; H Schilling; A Wessing
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

5.  Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma.

Authors:  Ahmet M Sarici; Halit Pazarli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-04       Impact factor: 3.117

6.  Cyclooxygenase-2 expression in human irradiated uveal melanomas.

Authors:  Pinar C Ozdal; Sonia Callejo; Amanda L Caissie; Chaim Edelstein; Silvin Bakalian; Raul N G Vianna; Miguel N Burnier
Journal:  Int Ophthalmol       Date:  2007-06-30       Impact factor: 2.031

7.  Histopathologic Patterns of Recurrent Choroidal Melanoma Following I-125 Plaque Brachytherapy.

Authors:  Jose J Echegaray; Thomas Plesec; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2019-06-18

8.  Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings.

Authors:  Chau M Pham; Steven M Couch; George J Harocopos
Journal:  Ocul Oncol Pathol       Date:  2017-08-23

9.  Histopathologic and MR Imaging Appearance of Spontaneous and Radiation-Induced Necrosis in Uveal Melanomas: Initial Results.

Authors:  Pietro Valerio Foti; Corrado Inì; Giuseppe Broggi; Renato Farina; Stefano Palmucci; Corrado Spatola; Rocco Luca Emanuele Liardo; Roberto Milazzotto; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Massimo Venturini; Francesco Giurazza; Teresio Avitabile; Antonio Basile
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.